Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limaprost versus imrecoxib, each combined with mecobalamin, for lumbar spinal stenosis
ChiCTR2300073153Phase 4Not yet recruiting
- Sponsor
- Peking University Shougang Hospital
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of limaprost, imrecoxib and mecobalamin in lumbar spinal stenosis (LSS) (2 arms), sponsored by Peking University Shougang Hospital. Primary endpoint: Improvement rate of JOA score after 8 weeks of treatment. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
limaprostimrecoxibmecobalamin
03
Conditions
lumbar spinal stenosis (LSS)
Beyond the preview
Go deeper on ChiCTR2300073153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073153.